Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (927) 927
niacinamide - analogs & derivatives (723) 723
phenylurea compounds (722) 722
index medicus (632) 632
male (599) 599
benzenesulfonates - administration & dosage (595) 595
female (496) 496
animals (436) 436
pyridines - administration & dosage (435) 435
oncology (406) 406
benzenesulfonates - therapeutic use (372) 372
sorafenib (364) 364
middle aged (340) 340
pyridines - therapeutic use (282) 282
aged (281) 281
cancer (258) 258
benzenesulfonates - adverse effects (251) 251
benzenesulfonates - pharmacology (249) 249
treatment outcome (246) 246
adult (239) 239
pyridines - adverse effects (217) 217
kidney neoplasms - drug therapy (211) 211
antineoplastic agents - therapeutic use (202) 202
carcinoma, renal cell - drug therapy (201) 201
mice (185) 185
antineoplastic combined chemotherapy protocols - therapeutic use (183) 183
antineoplastic agents - administration & dosage (182) 182
rats (166) 166
liver neoplasms - drug therapy (152) 152
carcinoma, hepatocellular - drug therapy (147) 147
pharmacology & pharmacy (146) 146
care and treatment (136) 136
antineoplastic agents - adverse effects (128) 128
bevacizumab (124) 124
protein kinase inhibitors - therapeutic use (122) 122
pyridines - pharmacology (122) 122
cell line, tumor (119) 119
research (117) 117
protein kinase inhibitors - administration & dosage (111) 111
sunitinib (110) 110
kidney neoplasms - pathology (108) 108
dose-response relationship, drug (107) 107
aged, 80 and over (104) 104
endothelial growth-factor (101) 101
indoles - administration & dosage (96) 96
administration, oral (94) 94
angiogenesis (93) 93
benzenesulfonates - pharmacokinetics (91) 91
drug administration schedule (91) 91
therapy (91) 91
time factors (90) 90
pyrroles - administration & dosage (85) 85
antitumor-activity (84) 84
drug therapy (84) 84
renal cell carcinoma (84) 84
chemotherapy (83) 83
hepatocellular carcinoma (83) 83
antibodies, monoclonal, humanized (81) 81
antineoplastic agents (80) 80
article (79) 79
protein kinase inhibitors - adverse effects (79) 79
renal-cell carcinoma (79) 79
antineoplastic combined chemotherapy protocols - adverse effects (78) 78
prognosis (77) 77
antimitotic agents (75) 75
expression (75) 75
indoles - therapeutic use (75) 75
neoplasms - drug therapy (75) 75
disease-free survival (74) 74
pyrroles - therapeutic use (74) 74
benzenesulfonates (73) 73
apoptosis (72) 72
disease models, animal (72) 72
rats, sprague-dawley (71) 71
antineoplastic agents - pharmacology (69) 69
interferon-alpha (69) 69
survival (68) 68
carcinoma, renal cell (67) 67
mice, nude (66) 66
carcinoma, hepatocellular - pathology (65) 65
liver neoplasms - pathology (65) 65
carcinoma, renal cell - secondary (64) 64
metastasis (64) 64
neoplasm staging (64) 64
clinical trials as topic (63) 63
medicine & public health (62) 62
carcinoma, renal cell - pathology (61) 61
retrospective studies (61) 61
survival rate (60) 60
sirolimus - analogs & derivatives (59) 59
liver cancer (58) 58
vascular endothelial growth factor (58) 58
carcinoma (57) 57
pharmacokinetics (57) 57
xenograft model antitumor assays (57) 57
cell proliferation - drug effects (56) 56
drug synergism (56) 56
indoles - adverse effects (56) 56
tumors (56) 56
raf kinase (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1133) 1133
German (24) 24
Russian (18) 18
French (13) 13
Japanese (11) 11
Chinese (8) 8
Spanish (7) 7
Italian (4) 4
Hungarian (3) 3
Czech (1) 1
Dutch (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
by Bo Gao and Shang Yeap and Arthur Clements and Bavanthi Balakrishnar and Mark Wong and Howard Gurney
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
by Toni K. Choueiri and Fabio A.B. Schutz and Youjin Je and Jonathan E. Rosenberg and Joaquim Bellmunt
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2280 - 2285
Purpose Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers.... 
GROWTH-FACTOR RECEPTOR | CANCER-PATIENTS | THERAPY | ONCOLOGY | BEVACIZUMAB | PATHWAY | MECHANISMS | INHIBITOR | HYPERTENSION | 1ST-LINE | RENAL-CELL CARCINOMA | Niacinamide - analogs & derivatives | Thromboembolism - chemically induced | Humans | Middle Aged | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thromboembolism - epidemiology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Incidence | Angiogenesis Inhibitors - administration & dosage | Pyridines - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Angiogenesis Inhibitors - adverse effects | Arterial Occlusive Diseases - chemically induced | Pyridines - administration & dosage | Risk Assessment | Administration, Oral | Risk Factors | Arterial Occlusive Diseases - epidemiology | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines – Lessons for design of combination targeted therapy
by Park, Brian J and Whichard, Zakary L and Corey, Seth J
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Cell culture | Values | Cell division | Cytotoxicity | Regression analysis | Kinases | Cancer therapies | Cell growth | Cell cycle | Software | Mutation | Drug dosages | Methods | Tumors | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
by Hutson, Thomas E and Figlin, Robert A and Kuhn, John G and Motzer, Robert J
The Oncologist, ISSN 1083-7159, 10/2008, Volume 13, Issue 10, pp. 1084 - 1096
Learning Objectives After completing this course, the reader should be able to: Evaluate the recommended clinical doses and the associated safety data for... 
Dosing | Temsirolimus | Sunitinib | Safety | Renal cell carcinoma | Sorafenib | MAMMALIAN TARGET | SOLID TUMORS | ANTITUMOR-ACTIVITY | FACTOR RECEPTOR | CANCER-THERAPY | INTRAVENOUS-INFUSION | PHASE-III TRIAL | INTERFERON-ALPHA | ONCOLOGY | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Recombinant Proteins | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Carcinoma, Renal Cell - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Carcinoma, Renal Cell - pathology | Interferon-alpha - administration & dosage | Sirolimus - administration & dosage | Indoles - adverse effects | Antibodies, Monoclonal - administration & dosage | Kidney Neoplasms - pathology | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
by Mark J. Ratain and Tim Eisen and Walter M. Stadler and Keith T. Flaherty and Stan B. Kaye and Gary L. Rosner and Martin Gore and Apurva A. Desai and Amita Patnaik and Henry Q. Xiong and Eric Rowinsky and James L. Abbruzzese and Chenghua Xia and Ronit Simantov and Brian Schwartz and Peter J. O'Dwyer
Journal of Clinical Oncology, ISSN 0732-183X, 06/2006, Volume 24, Issue 16, pp. 2505 - 2512
This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and... 
Niacinamide - analogs & derivatives | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Male | Treatment Outcome | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - adverse effects | Disease-Free Survival | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Survival Analysis | Adult | Female | Aged | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Kidney Neoplasms - secondary
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
by Ghassan K. Abou-Alfa and Lawrence Schwartz and Sergio Ricci and Dino Amadori and Armando Santoro and Arie Figer and Jacques De Greve and Jean-Yves Douillard and Chetan Lathia and Brian Schwartz and Ian Taylor and Marius Moscovici and Leonard B. Saltz
Journal of Clinical Oncology, ISSN 0732-183X, 09/2006, Volume 24, Issue 26, pp. 4293 - 4300
Purpose This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity,... 
BAY-43-9006 | HEPATITIS-C VIRUS | TUMOR PROGRESSION | ONCOLOGY | KINASE | DOXORUBICIN | GENE-EXPRESSION | RESISTANCE | COMBINATION CHEMOTHERAPY | RAF/MEK/ERK PATHWAY | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Predictive Value of Tests | Extracellular Signal-Regulated MAP Kinases - blood | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | RNA, Neoplasm - blood | Benzenesulfonates - adverse effects | Liver Neoplasms - blood | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Carcinoma, Hepatocellular - genetics | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Carcinoma, Hepatocellular - blood | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Treatment Outcome | Biomarkers, Tumor - blood | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
by Lee, W.J and Lee, J.L and Chang, S.E and Lee, M.W and Kang, Y.K and Choi, J.H and Moon, K.C and Koh, J.K
British Journal of Dermatology, ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
Summary Background  The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and... 
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | THERAPY | HAIR | MANAGEMENT | KIT | IMATINIB | HAND-FOOT | FOOT SKIN REACTION | DERMATOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
by José Baselga and José Getúlio Martins Segalla and Henri Roché and Auro del Giglio and Hélio Pinczowski and Eva M. Ciruelos and Sebastião Cabral Filho and Patricia Gómez and Brigitte Van Eyll and Begoña Bermejo and Antonio Llombart and Bernardo Garicochea and Miguel Ángel Climent Durán and Paulo Marcelo Gehm Hoff and Marc Espié and Andre Augusto Junior Gemeinder de Moraes and Ronaldo Albuquerque Ribeiro and Clarissa Mathias and Miguel Gil Gil and Belén Ojeda and Josefa Morales and Sunhee Kwon Ro and Shell Li and Frederico Costa
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 13, pp. 1484 - 1491
Purpose Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial... 
PHASE-III TRIAL | DESIGN | THERAPY | ONCOLOGY | BEVACIZUMAB | GROWTH | ANTIBODY | TUMOR ANGIOGENESIS | MULTIKINASE INHIBITOR | PROGRESSION | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Breast Neoplasms - chemistry | Breast Neoplasms - enzymology | Fluorouracil - administration & dosage | Time Factors | Brazil | Adult | Female | Pyridines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Administration, Oral | Biomarkers, Tumor - analysis | Neoplasm Invasiveness | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
by Nilofer S. Azad and Edwin M. Posadas and Virginia E. Kwitkowski and Seth M. Steinberg and Lokesh Jain and Christina M. Annunziata and Lori Minasian and Gisele Sarosy and Herbert L. Kotz and Ahalya Premkumar and Liang Cao and Deborah McNally and Catherine Chow and Helen X. Chen and John J. Wright and William D. Figg and Elise C. Kohn
Journal of Clinical Oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 22, pp. 3709 - 3714
Purpose Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor. Bevacizumab is a monoclonal antibody targeted against VEGF. We... 
TRIAL | LUNG-CANCER | BAY-43-9006 | ONCOLOGY | SAFETY | COLORECTAL-CANCER | TYROSINE KINASE | PHASE-II | OVARIAN-CANCER | REFRACTORY SOLID TUMORS | RENAL-CELL CARCINOMA | Niacinamide - analogs & derivatives | raf Kinases - antagonists & inhibitors | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Ovarian Neoplasms - drug therapy | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Vascular Endothelial Growth Factor A - blood | Neoplasms - enzymology | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
by Hiroto Inaba and Jeffrey E. Rubnitz and Elaine Coustan-Smith and Lie Li and Brian D. Furmanski and Gerard P. Mascara and Kenneth M. Heym and Robbin Christensen and Mihaela Onciu and Sheila A. Shurtleff and Stanley B. Pounds and Ching-Hon Pui and Raul C. Ribeiro and Dario Campana and Sharyn D. Baker
Journal of Clinical Oncology, ISSN 0732-183X, 08/2011, Volume 29, Issue 24, pp. 3293 - 3300
Purpose To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in... 
TRIALS | CELLS | SIGNALING PATHWAYS | ACTIVATION | THERAPY | ONCOLOGY | FLT3 | ACUTE MYELOGENOUS LEUKEMIA | RESIDUAL DISEASE | KINASE INHIBITORS | ACUTE MYELOID-LEUKEMIA | Niacinamide - analogs & derivatives | Protein Kinase Inhibitors - pharmacokinetics | Recurrence | Pyridines - administration & dosage | Drug Administration Schedule | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia - drug therapy | Drug Resistance, Neoplasm | Male | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Cytarabine - administration & dosage | Arabinonucleosides - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Adenine Nucleotides - pharmacokinetics | Arabinonucleosides - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Female | Adenine Nucleotides - administration & dosage | Child | Index Medicus | Hema7 | Pedi18 | Hema5 | Hema6 | Faze | Original Reports | Pedi3
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma
by Bhojani, Naeem and Jeldres, Claudio and Patard, Jean-Jacques and Perrotte, Paul and Suardi, Nazareno and Hutterer, Georg and Patenaude, François and Oudard, Stéphane and Karakiewicz, Pierre I
European Urology, ISSN 0302-2838, 2007, Volume 53, Issue 5, pp. 917 - 930
Abstract Objective To provide a systematic review of the side effects associated with sorafenib, sunitinib, and temsirolimus and to provide an outline of... 
Urology | Temsirolimus | Side effects | Sunitinib | Sorafenib | sunitinib | MAMMALIAN TARGET | BAY-43-9006 | sorafenib | DAYS ON/7 DAYS | RAF KINASE | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | INTERFERON-ALPHA | temsirolimus | PHARMACOKINETICS | UROLOGY & NEPHROLOGY | side effects | REFRACTORY SOLID TUMORS | PHASE-I | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor | Drug-Related Side Effects and Adverse Reactions - prevention & control | Prognosis | Humans | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Carcinoma, Renal Cell - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Sirolimus - administration & dosage | Indoles - adverse effects | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Metastasis | Life Sciences | Pharmaceutical sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Advanced-stage hepatocellular carcinoma: Transarterial chemoembolization versus sorafenib
by Pinter, Matthias and Hucke, Florian and Graziadei, Ivo and Vogel, Wolfgang and Maieron, Andreas and Königsberg, Robert and Stauber, Rudolf and Grünberger, Birgit and Müller, Christian and Kölblinger, Claus and Peck-Radosavljevic, Markus and Sieghart, Wolfgang
Radiology, ISSN 0033-8419, 2012, Volume 263, Issue 2, pp. 590 - 599
Purpose: To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC).... 
SURVIVAL | RANDOMIZED CONTROLLED TRIAL | MAIN PORTAL-VEIN | EXTRAHEPATIC METASTASES | MANAGEMENT | PROGNOSIS | ARTERIAL EMBOLIZATION | LIPIODOL CHEMOEMBOLIZATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | ADHERENCE | SYMPTOMATIC TREATMENT | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Liver Neoplasms - therapy | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Ethiodized Oil - adverse effects | Benzenesulfonates - adverse effects | Chemoembolization, Therapeutic - methods | Ethiodized Oil - administration & dosage | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Contrast Media - administration & dosage | Adult | Female | Liver Neoplasms - pathology | Retrospective Studies | Doxorubicin - administration & dosage | Pyridines - administration & dosage | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Chi-Square Distribution | Disease Progression | Magnetic Resonance Imaging | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Carcinoma, Hepatocellular - therapy | Neoplasm Staging | Doxorubicin - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Unusual Short-Term Complete Response to Two Regimens of Cytotoxic Chemotherapy in a Patient with Poorly Differentiated Thyroid Carcinoma
by Crouzeix, Geneviève and Michels, Jean-Jacques and Sevin, Emmanuel and Aide, Nicolas and Vaur, Dominique and Bardet, Stéphane and French TUTHYREF Network and French TUTHYREF network and for the French TUTHYREF network
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 09/2012, Volume 97, Issue 9, pp. 3046 - 3050
Context: Treatment modalities for progressive iodine-refractory poorly differentiated thyroid carcinomas are not yet well defined. Molecular targeted therapy... 
DOXORUBICIN PLUS CISPLATIN | CRITERIA | PHASE-II TRIAL | RECIST | SOLID TUMORS | ENDOCRINOLOGY & METABOLISM | EXPERIENCE | SORAFENIB | CANCER | Niacinamide - analogs & derivatives | Humans | Middle Aged | Tomography, X-Ray Computed | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Indoles - administration & dosage | Cisplatin - administration & dosage | Thyroid Neoplasms - therapy | Antineoplastic Agents, Phytogenic - administration & dosage | Iodine Radioisotopes - therapeutic use | Lung Neoplasms - secondary | Pyrroles - administration & dosage | Fatal Outcome | Female | Quinazolines - administration & dosage | Paclitaxel - administration & dosage | Radiopharmaceuticals | Doxorubicin - administration & dosage | Piperidines - administration & dosage | Pyridines - administration & dosage | Combined Modality Therapy | Thyroidectomy | Antibiotics, Antineoplastic - administration & dosage | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fluorodeoxyglucose F18
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway
by Kurosu, Tetsuya and Ohki, Manabu and Wu, Nan and Kagechika, Hiroyuki and Miura, Osamu
Cancer Research, ISSN 0008-5472, 05/2009, Volume 69, Issue 9, pp. 3927 - 3936
Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive... 
BAY-43-9006 | ONCOLOGY | MCL-1 | BCR-ABL | IMATINIB | GROWTH | DOWN-REGULATION | MYELOGENOUS LEUKEMIA | RECEPTOR | MULTIKINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Apoptosis - drug effects | Humans | Pyrazines - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Fusion Proteins, bcr-abl - biosynthesis | Interleukin-3 - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Benzenesulfonates - pharmacology | Caspases - metabolism | Acetophenones - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Boronic Acids - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Protein-Tyrosine Kinases - biosynthesis | Bortezomib | Pyridines - administration & dosage | Nitrophenols - administration & dosage | Mitochondria - drug effects | Pyrimidines - pharmacology | Enzyme Activation - drug effects | Imatinib Mesylate | Piperazines - pharmacology | Drug Synergism | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Protein Kinase Inhibitors - administration & dosage | Benzopyrans - administration & dosage | Fusion Proteins, bcr-abl - genetics | Biphenyl Compounds - administration & dosage | Fusion Proteins, bcr-abl - antagonists & inhibitors | K562 Cells | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Apoptosis - physiology | Benzamides | Mutation | Mitochondria - physiology | Sulfonamides - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights